[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies].
Beta-adrenoceptor agonists have several pharmacological actions in the lung which affect airway function. They have a direct relaxant effect on human bronchial smooth muscle and several additional properties, including attenuation of mast cell mediater release, reduction in airway microvascular leakage, and inhibition of cholinergic neurotransmission within the airway, in vitro. However, direct evidence in vivo for any anti-inflammatory effects of beta-adrenocepter agonists is limited. We reported that beta-agonists (procaterol, salmeterol) inhibited significantly I. A. R. and L. A. R. Salmeterol also reduced urinary secretion of LTE4. It is suggested that beta-agonists have some of anti-allergic effects in the clinical pharmacological study. From recent clinical studies, it is recommended on demand use more than regular use of inhaled beta-agonists.
Horikoshi
S
S
First Department of Internal Medicine, School of Medicine, Showa University.
Kokubu
F
F
Adachi
M
M
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D001249:Asthma / Q000276:immunology*; D001980:Bronchi / Q000166:cytology / Q000276:immunology; D016535:Bronchial Hyperreactivity; D001985:Bronchial Provocation Tests; D006801:Humans; D066298:In Vitro Techniques; D018836:Inflammation Mediators / Q000378:metabolism; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D017999:Leukotriene E4 / Q000652:urine; D008407:Mast Cells / Q000378:metabolism; D017265:Procaterol / Q000494:pharmacology*; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D018926:Anti-Allergic Agents; D018836:Inflammation Mediators; D018799:Intercellular Adhesion Molecule-1; D000068299:Salmeterol Xinafoate; D017999:Leukotriene E4; D000420:Albuterol; D017265:Procaterol